Matches in Wikidata for { <http://www.wikidata.org/entity/Q99555161> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q99555161 description "article scientifique publié en 2020" @default.
- Q99555161 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99555161 description "scientific article published on 13 September 2020" @default.
- Q99555161 description "wetenschappelijk artikel" @default.
- Q99555161 description "наукова стаття, опублікована 13 вересня 2020" @default.
- Q99555161 name "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 name "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 type Item @default.
- Q99555161 label "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 label "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 prefLabel "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 prefLabel "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 P1433 Q99555161-CC1D138C-ECEB-49FA-8AC3-0E2F29AD69B9 @default.
- Q99555161 P1476 Q99555161-BE93F6AE-1EB6-4935-AE93-84A12131DC45 @default.
- Q99555161 P2093 Q99555161-132C75BF-E274-4D3A-A12B-55DEE7362543 @default.
- Q99555161 P2093 Q99555161-5DD15757-0F54-4B10-8A77-59FC37D0C810 @default.
- Q99555161 P2093 Q99555161-A91B3C8D-7013-4196-9B47-B9031B46640A @default.
- Q99555161 P2093 Q99555161-F8A56503-AC28-41FF-BAD8-E295F973AC74 @default.
- Q99555161 P304 Q99555161-35C03C90-F1C0-4807-843A-5CAC3F95D861 @default.
- Q99555161 P31 Q99555161-11EBEB82-3F17-470B-9B7D-0144987A430C @default.
- Q99555161 P356 Q99555161-7378D71A-C61B-4A92-94D6-FDE76D39D70A @default.
- Q99555161 P577 Q99555161-E73C4A1B-55F3-425F-AE98-5A2638554858 @default.
- Q99555161 P698 Q99555161-CCEF1B92-6EFE-4496-9D9B-600A1B6740AD @default.
- Q99555161 P921 Q99555161-605DBA2F-1BBC-4C0D-985E-46E4BB2CA5D4 @default.
- Q99555161 P356 J.EJPS.2020.105552 @default.
- Q99555161 P698 32937212 @default.
- Q99555161 P1433 Q5412738 @default.
- Q99555161 P1476 "A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide" @default.
- Q99555161 P2093 "Edmund Kostewicz" @default.
- Q99555161 P2093 "Maja Chronowska" @default.
- Q99555161 P2093 "Maximo Pettarin" @default.
- Q99555161 P2093 "Michael B Bolger" @default.
- Q99555161 P304 "105552" @default.
- Q99555161 P31 Q13442814 @default.
- Q99555161 P356 "10.1016/J.EJPS.2020.105552" @default.
- Q99555161 P577 "2020-09-13T00:00:00Z" @default.
- Q99555161 P698 "32937212" @default.
- Q99555161 P921 Q461809 @default.